Assenagon Asset Management S.A. Has $8.55 Million Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)

Assenagon Asset Management S.A. lifted its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 63.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 710,713 shares of the company's stock after buying an additional 275,260 shares during the quarter. Assenagon Asset Management S.A. owned about 1.12% of Evolus worth $8,550,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in the business. Tang Capital Management LLC lifted its holdings in Evolus by 3.1% in the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock worth $55,171,000 after purchasing an additional 150,000 shares during the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Evolus by 10.8% during the fourth quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company's stock worth $34,557,000 after buying an additional 305,300 shares during the last quarter. Caligan Partners LP boosted its position in shares of Evolus by 22.7% in the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock valued at $29,724,000 after acquiring an additional 498,900 shares during the period. Millennium Management LLC increased its position in Evolus by 29.1% during the fourth quarter. Millennium Management LLC now owns 1,368,423 shares of the company's stock worth $15,107,000 after acquiring an additional 308,753 shares during the period. Finally, Boothbay Fund Management LLC raised its stake in Evolus by 30.9% during the 4th quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company's stock valued at $14,217,000 after purchasing an additional 304,065 shares during the last quarter. 90.69% of the stock is owned by institutional investors.

Insider Activity

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $60,147.36. Following the sale, the chief marketing officer now owns 95,671 shares in the company, valued at approximately $1,268,597.46. The trade was a 4.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rui Avelar sold 27,904 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the transaction, the insider now directly owns 362,467 shares of the company's stock, valued at $4,806,312.42. This represents a 7.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,353 shares of company stock worth $881,251 in the last 90 days. Corporate insiders own 5.90% of the company's stock.

Evolus Price Performance

EOLS traded down $0.05 during midday trading on Monday, hitting $9.88. The company had a trading volume of 118,019 shares, compared to its average volume of 739,286. Evolus, Inc. has a twelve month low of $8.67 and a twelve month high of $17.82. The company has a market capitalization of $637.22 million, a PE ratio of -10.88 and a beta of 1.00. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The firm's 50-day simple moving average is $10.31 and its 200-day simple moving average is $11.77.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. BTIG Research assumed coverage on Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price target for the company. Needham & Company LLC restated a "buy" rating and issued a $22.00 target price on shares of Evolus in a research note on Thursday, May 8th. Barclays raised their target price on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $23.75.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.